Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.

NCT00409851 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00409851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00409851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2003
Completion date
March 31, 2005
Enrollment
1,293 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension